Anti-inflammatory effects of C-peptide prevent endothelial dysfunction in Type 1 diabetes

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 59-70

  Cifarelli, Vincenza ^a   Trucco, Massimo ^a   Luppi, Patrizia ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

C peptide; Complications; Diabetes; Endothelium; Inflammation; Vascular

Indexed keywords

C PEPTIDE; CD36 ANTIGEN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROINSULIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL INTERACTION; CELL POPULATION; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; CYTOLOGY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; POLYDIPSIA; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

EID: 79951712960     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152211794519403     Document Type: Review

References (118)

1. Steiner, D.; Oyer, P. Biosynthesis of insulin and a probableprecursor of insulin by a human islet cell adenoma. Proc. Natl. Acad. Sci. USA, 1967, 57, 473-481.
2. Samnegard, B.; Brundin, T. Renal extraction of insulin and Cpeptidein man before and after a glucose meal. Clin. Physiol., 2001, 21, 164-171.
3. Polonsky, K.; O'Meara, N. Secretion and metabolism of insulin, proinsulin and C-peptide. In: DeGroot, L.; Jameson, J.; Eds.;Endocrinology, Philadelphia, USA, 2001; Vol. 1, pp. 697-711.
4. Polonsky, K.; Rubenstein, A. C-peptide as a measure of thesecretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes, 1984, 33, 486-494.
5. Sjöberg, S.; Gunnarsson, R.; Gjötterberg, M.; Lefvert, A.K.; Persson, A.; Ostman, J. Residual insulin production, glycemiccontrol and prevalence of microvascular lesions andpolyneuropathy in long-term type 1 (insulin-dependent) diabetesmellitus. Diabetologia, 1987, 30(4), 208-213.
6. Zerbini, G.; Mangili, R.; Luzi, L. Higher post-absorptive C-peptidelevels in type 1 diabetic patients without renal complications. Diabet. Med., 1999, 16, 1048-1049.
7. Fioretto, P.; Steffes, M.; Sutherland, D.; Goetz, F.; Mauer, M. Reversal of lesions of diabetic nephropathy after pancreastransplantation. N. Engl. J. Med., 1998, 339, 69-75.
8. Fiorina, P.; Folli, F.; Zerbini, G.; Maffi, P.; Gremizzi, C.; Di Carlo, V.; Socci, C.; Bertuzzi, F.; Kashgarian, M.; Secchi, A. Islettransplantation is associated with improvement of renal functionamong uremic patients with type I diabetes mellitus and kidneytransplants. J. Am. Soc. Nephrol., 2003, 14, 2150-2158.
9. Lee, T.C.; Barshes, N.R.; Agee, E.E.; O'Mahoney, C.A.; Brunicardi, F.C.; Goss, J.A. The effect of whole organ pancreastransplantation and PIT on diabetic complications. Curr. Diab. Rep., 2006, 6(4), 323-327.
10. Shapiro, A.M.; Ricordi, C.; Hering, B.J.; Auchincloss, H.; Lindblad, R.; Robertson, R.P.; Secchi, A.; Brendel, M.D.; Berney, T.; Brennan, D.C.; Cagliero, E.; Alejandro, R.; Ryan, E.A.; DiMercurio, B.; Morel, P.; Polonsky, K.S.; Reems, J.A.; Bretzel, R.G.; Bertuzzi, F.; Froud, T.; Kandaswamy, R.; Sutherland, D.E.; Eisenbarth, G.; Segal, M.; Preiksaitis, J.; Korbutt, G.S.; Barton, F.B.; Viviano, L.; Seyfert-Margolis, V.; Bluestone, J.; Lakey, J.R. International trial of the Edmonton protocol for islet transplantation.N. Engl. J. Med., 2006, 355(13), 1318-1330.
11. Valdes-Gonzalez, R.; Rodriguez-Ventura, A.L.; White, D.J.G.; Bracho-Blanchet, E.; Castillo, A.; Ramirez-Gonzales, B.; Lopez-Santos, M.G.; Leon-Mancilla, B.H.; Dorantes, L.M. Long term follow-up of patients with type 1 diabetes transplanted with neonatalpig islets. Clin. Exp. Immunol., 2010, 162(3), 537-542.
12. Panero, F.; Novelli, G.; Zucco, C.; Fornengo, P.; Perotto, M.; Segre,. O.; Grassi, G.; Cavallo-Perin, P.; Bruno, G. Fasting plasmaC-peptide and micro- and macrovascular complications in a largeclinic-based cohort of type 1 diabetic patients. Diabetes Care, 2009, 32(2), 301-305.
13. Wahren, J.; Ekberg, K.; Jornvall, H. C-peptide is a bioactive peptide. Diabetologia, 2007, 50, 503-509.
14. Hills, C.E.; Brunskill, N.J. Intracellular signaling by C-peptide. Exp. Diab. Res., 2008, 635158.
15. Vish, M.G.; Mangeshkar, P.; Piraino, G.; Denenberg, A.; Hake, P.W.; O'Connor, M.; Zingarelli, B. Proinsulin C-peptide exertsbeneficial effects in endotoxic shock in mice. Critic. Care Med., 2007, 35, 1348-1355.
16. Johansson, B.L.; Borg, K.; Fernqvist-Forbes, E.; Kernell, A.; Odergren, T.; Wahren, J. Beneficial effects of C-peptide on incipientnephropathy and neuropathy in patients with type 1 diabetes: athree-month study. Diabet. Med., 2000, 17, 181-189.
17. Ekberg, K.; Brismar, T.; Johansson, B.L.; Lindstrom, P.; Juntll-Berggren, L.; Norrby, A.; Berne, C.; Arnqvist, H.J.; Bolinder, J.; Wahren, J. C-Peptide replacement therapy and sensory nerve functionin type 1 diabetic neuropathy. Diabetes Care, 2007, 30, 71-767.
18. Hansen, A.; Johansson, B.L.; Wahren, J.; von Bibra, H. C-peptideexerts beneficial effects on myocardial blood flow and function inpatients with type 1 diabetes. Diabetes, 2002, 51, 3077-30828.
19. Johansson, B.L.; Wahren, J.; Pernow, J. C-peptide increases forearmblood flow in patients with type 1 diabetes via a nitric oxidedependentmechanism. Am. J. Physiol. Endocrinol. Metab., 2003, 285, E864-8709.
20. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmunedisease. N. Engl. J. Med., 1986, 314, 1360-1368.
21. Libby, P.; Nathan, D.M.; Abraham, K.; Brunzell, J.D.; Fradkin, J.E.; Haffner, S.M.; Hsueh, W.; Rewers, M.; Roberts, B.T.; Savage, P.J.; Skarlatos, S.; Wassef, M.; Rabadan-Diehl, C. Report of thenational heart, lung, and blood institute-national institute ofdiabetes and digestive and kidney diseases working group oncardiovascular complications of type 1 diabetes mellitus. Circulation, 2005, 111, 3489-3493.
22. Zatz, R.; Brenner, B.M. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am. J. Med., 1986, 80, 443-453.
23. Nathan, D.M. Long-term complications of diabetes mellitus. N. Engl. J. Med., 1993, 328, 1676-1685.
24. Jensen, T.; Bjerre-Knudsen, J.; Feldt-Rasmussen, B.; Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 1989, 1, 461-463.
25. Brownlee, M. Biochemistry and molecular cell biology of diabeticcomplications. Nature, 2001, 414, 813-820.
26. Conrad, B.; Weidmann, E.; Trucco, G.; Rudert, W.A.; Behboo, R.;, Ricordi, C.; Rodriguez-Rilo, H.; Finegold, D.; Trucco, M. Evidencefor superantigen involvement in insulin-dependent diabetesmellitus aetiology. Nature, 1994, 371, 351-355.
27. Goodier, M.R.; Nawroly, N.; Beyan, H.; Hawa, M.; Leslie, R.D.; Londei, M. Identical twins discordant for type 1 diabetes show adifferent pattern of in vitro CD56+ cell activation. Diab. Metab. Res. Rev., 2006, 22, 367-375.
28. Wilson, S.B.; Kent, S.C.; Patton, K.T.; Orban, T.; Jackson, R.A.; Exley, M.; Porcelli, S.; Schatz, D.A.; Atkinson, M.A.; Balk, S.P.; Strominger, J.L.; Hafler, D.A. Extreme Th1 bias of invariantValpha24JalphaQ T cells in type 1 diabetes. Nature, 1998, 391, 177-181.
29. Adler, T.; Akiyama, H.; Herder, C.; Kolb, H.; Burkart V. Heatshock protein 60 elicits abnormal response in macrophages ofdiabetes-prone non-obese diabetic mice. Biochem. Biophys. Res. Commun., 2002, 294, 592-596.
30. Beyan, H.; Goodier, M.R.; Nawroly, N.S.; Hawa, M.I.; Bustin, S.A.; Ogunkolade, W.B.; Londei, M.; Yousaf, N.; Leslie, RD. Altered monocyte cyclooxygenase response to lipopolysaccharidein type 1 diabetes. Diabetes, 2006, 55, 3439-3445.
31. Kolb-Bachofen, V.; Kolb, H. A role for macrophages in thepathogenesis of type 1 diabetes. Autoimmunity, 1989, 3, 145-154.
32. Hanenberg, H.; Kolb-Bachofen, V.; Kantwerk-Funke, G.; Kolb, H. Macrophage infiltration precedes and is a prerequisite forlymphocytic insulitis in pancreatic islets of pre-diabetic BB rats. Diabetologia, 1989, 32, 126-134.
33. Eizirik, D.L.; Colli, M.L.; Ortis, F. The role of inflammation ininsulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol., 2009, 5, 219-226.
34. Schalkwijk, C.G.; Poland, D.C.; van Dijk, W.; Kok, A.; Emeis, J.J.; Drager, A.M.; Doni, A.; van Hinsbergh, V.W.; Stehouwer, C.D. Plasma concentration of C-reactive protein is increased in type Idiabetic patients without clinical macroangiopathy and correlateswith markers of endothelial dysfunction: evidence for chronicinflammation. Diabetologia, 1999, 42, 351-357.
35. Kilpatrick, E.S.; Keevil, B.G.; Jagger, C.; Spooner, R.J.; Small, M. Determinants of raised C-reactive protein concentration in type 1diabetes. QJM, 2000, 93, 231-236.
36. Lechleitner, M.; Koch, T.; Herold, M.; Dzien, A.; Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1diabetes mellitus and its association with glycaemic control andcardiovascular risk factors. J. Intern. Med., 2000, 248, 67-76.
37. Devaraj, S.; Cheung, A.T.; Jialal, I.; Griffen, S.C.; Nguyen, D.; Glaser, N.; Aoki, T. Evidence of increased inflammation andmicrocirculatory abnormalities in patients with type 1 diabetes andtheir role in microvascular complications. Diabetes, 2007, 56, 2790-2796.
38. Devaraj, S.; Glaser, N.; Griffen, S.; Wang-Polagruto, J.; Miguelino, E.; Jialal, I. Increased monocytic activity and biomarkers ofinflammation in patients with type 1 diabetes. Diabetes, 2006, 55, 774-779.
39. Plesner, A.; Greenbaum, C.J.; Gaur, L.K.; Ernst, R.K.; Lernmark, A. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1diabetes mellitus patients are hypersensitive to lipopolysaccharidestimulation. Scand. J. Immunol., 2002, 56, 522-529.
40. Erbagci, A.B.; Tarakcioglu, M.; Coskun, Y.; Sivasli, E.; SibelNamiduru, E. Mediators of inflammation in children with type Idiabetes mellitus: cytokines in type I diabetic children. Clin. Biochem., 2001, 34, 645-650.
41. Cifarelli, V.; Libman, I.M.; Deluca, A.; Becker, D.; Trucco, M.; Luppi, P. Increased expression of monocyte CD11b (Mac-1) inoverweight recent-onset type 1 diabetic children. Rev. Diabet. Stud., 2007, 4, 112-117.
42. Litherland, S.A.; Xie, X.T.; Hutson, A.D.; Wasserfall, C.; Whittaker, D.S.; She, J.X.; Hofig, A.; Dennis, M.A.; Fuller, K.; Cook, R.; Schatz, D.; Moldawer, L.L.; Clare-Salzler, M.J. Aberrantprostaglandin synthase 2 expression defines an antigen-presentingcell defect for insulin-dependent diabetes mellitus. J. Clin. Invest., 1999, 104, 515-523.
43. Schram, M.T.; Chaturvedi, N.; Schalkwijk, C.; Giorgino, F.; Ebeling, P.; Fuller, J.H.; Stehouwer, C.D.; EURODIABProspective Complications Study. Vascular risk factors andmarkers of endothelial function as determinants of inflammatorymarkers in type 1 diabetes: the EURODIAB ProspectiveComplications Study. Diabetes Care, 2003, 26, 2165-2173.
44. Saraheimo, M.; Teppo, A.M.; Forsblom, C.; Fagerudd, J.; Groop, P.H. Diabetic nephropathy is associated with low-gradeinflammation in Type 1 diabetic patients. Diabetologia, 2003, 46, 1402-1407.
45. Schalkwijk, C.G.; Ter Wee, P.M.; Stehouwer, C.D. Plasma levelsof AGE peptides in type 1 diabetic patients are associated withserum creatinine and not with albumin excretion rate: possible roleof AGE peptide-associated endothelial dysfunction. Ann. N.Y. Acad. Sci., 2005, 1043, 662-670.
46. Schmidt, A.M.; Hori, O.; Chen, J.X.; Li, J.F.; Crandall, J.; Zhang, J.; Cao, R.; Yan, S.D.; Brett, J.; Stern, D. Advanced glycationendproducts interacting with their endothelial receptor induceexpression of vascular cell adhesion molecule-1 (VCAM-1) incultured human endothelial cells and in mice. A potentialmechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest., 1995, 96, 1395-1403.
47. Yoder, M.C. Is endothelium the origin of endothelial progenitorcells? Atherioscler. Thromb. Vasc. Biol., 2010, 30, 1094-1103.
48. Versari, D.; Daghini, E.; Virdis, A.; Ghiadoni, L.; Taddei, S. Endothelialdysfunction as target for prevention of cardiovascular disease. Diabetes Care, 2009, 2, S314-321.
49. Hartge, M.M.; Kintscher, U.; Unger, T. Endothelial dysfunctionand its role in diabetic vascular disease. Endocrinol. Metab. Clin. North. Am., 2006, 35, 551-560.
50. Widlansky, M.E.; Gokce, N.; Keaney, J.F. Jr.; Vita, J.A. The clinicalimplication of endothelial dysfunction. J. Am. Coll. Cardiol., 2003, 42, 1149-1160.
51. Monnink, S.H.; van Haelst, P.L.; van Boven, A.J.; Stroes, E.S.; Tio, R.A.; Plokker, T.W.; Smit, A.J.; Veeger, N.J.; Crijns, H.J.; vanGilst, W.H. Endothelial dysfunction in patients with coronary arterydisease: a comparison of three frequently reported tests. J. Investig. Med., 2002, 50, 19-24.
52. Bolton, C.H.; Downs, L.G.; Victory, J.G.; Dwight, J.F.; Tomson, C.R.; Mackness, M.I.; Pinkney, J.H. Endothelial dysfunction inchronic renal failure: roles of lipoprotein oxidation and proinflammatorycytokines. Nephrol. Dial. Transplant., 2001, 16, 1189-1197.
53. Rizzoni, D.; Porteri, E.; Guelfi, D.; Muiesan, M.L.; Valentini, U.; Cimino, A.; Girelli, A.; Rodella, L.; Bianchi, R.; Sleiman, I.; Rosei, E.A. Structural alterations in subcutaneuos small arteries of normotensiveand hypertensive patients with non-insulin-dependentdiabetes mellitus. Circulation, 2001, 103, 1238-1244.
54. Endemann, D.H.; Pu, Q.; De Ciuceis, C.; Savoia, C.; Virdis, A.; Neves, M.F.; Touyz, R.M.; Schiffrin, E.L. Persistent remodeling ofresistance arteries in type 2 diabetic patients on antihypertensivetreatment. Hypertension, 2004, 43, 399-404.
55. Virdis, A.; Ghiadoni, L.; Cardinal, H.; Favilla, S.; Suranti, P.; Birindelli, R.; Magagna, A.; Bernini, G.; Salvetti, G.; Taddei, S.; Salvetti, A. Mechanisms responsible for endothelial dysfunctioninduced by fasting hyperhomocystinemia in normotensive subjectsand patients with essential hypertension. J. Am. Coll. Cardiol., 2001, 38, 1106-1115.
56. Green, D.J.; Walsh, J.H.; Maiorana, A.; Best, M.J.; Taylor, R.R.; O'Driscoll, J.G. Exercise-induced improvement in endothelial dysfunctionis not mediated by changes in CV risk factors: pooledanalysis of diverse patient populations. Am. J. Physiol. Heart. Circ. Physiol. 2003, 285, H2679-2687.
57. Piga, R.; Naito, Y.; Kokura, S.; Handa, O.; Yoshikawa, T. Shorttermhigh glucose exposure induces monocyte-endothelial cellsadhesion and transmigration by increasing VCAM-1 and MCP-1expression in human aortic endothelial cells. Atherosclerosis, 2007, 193, 328-334.
58. Johnstone, M.T.; Creager, S.J.; Scales, K.M.; Cusco, J.A.; Lee, B.K.; Creager, M.A. Impaired endothelium-dependent vasodilationin patients with insulin-dependent diabetes mellitus. Circulation, 1993, 88, 2510-2516.
59. Harrison, D.G. Cellular and molecular mechanisms of endothelialcell dysfunction. J. Clin. Invest., 1997, 100, 2153-2157.
60. Duh, E.; Aiello, L.P. Vascular endothelial growth factor and diabetes:the agonist versus antagonist paradox. Diabetes, 1999, 48, 1899-1906.
61. Gerszten, R.E.; Garcia-Zepeda, E.A.; Lim, Y.C.; Yoshida, M.; Ding, H.A.; Gimbrone, M.A., Jr., Luster, A.D.; Luscinskas, F.W.; Rosenzweig, A. MCP-1 and IL-18 trigger firm adhesion of monocytesto vascular endothelium under flow conditions. Nature, 1999, 398, 718-723.
62. Wilcox, J.N.; Nelken, N.A.; Coughlin, S.R.; Gordon, D.; Schall, T.J. Local expression of inflammatory cytokines in human atheroscleroticplaques. J. Atheroscler. Thromb., 1994, 1(Suppl. 1), 10-13.
63. Flier, J.S. Diabetes: the missing link with obesity? Nature, 2001, 409, 292-293.
64. Ceriello, A., dello Russo, P.; Amstad, P.; Cerrutti P. High glucoseinduces antioxidant enzymes in human endothelial cells in culture. Diabetes, 1996, 45, 471-477.
65. Ceolotto, G.; Gallo, A.; Papparella, I.; Franco, L.; Murphy, E.; Iori, E.; Pagnin, E.; Fadini, G.P.; Iori E, Albiero, M.; Semplicini, A.; Avogaro, A. Rosiglitazone reduces glucose-induced oxidativestress mediated by NAD(P)H oxidase via AMPK-dependentmechanism. Arterioscler. Thromb. Vasc. Biol., 2007, 27(12), 2627-2633.
66. Cohen, R.A. Dysfunction of vascular endothelium in diabetes mellitus. Circulation, 1993, 87(Suppl 5), 67-76.
67. Du, X.L.; Sui, G.Z.; Stockklauser-Färber, K.; Weiss, J.; Zink, S.; Schwippert, B.; Wu, Q.X.; Tschöpe, D.; Rösen, P. Induction ofapoptosis by high proinsulin and glucose in cultured human umbilicalvein endothelial cells is mediated by reactive oxygen species. Diabetologia, 1998, 41, 249-256.
68. Barchowsky, A.; Munro, S.R.; Morana, S.J.; Vincenti, M.P.; Treadwell, M. Oxidant-sensitive and phosphorylation-dependentactivation of NF-kappa B and AP-1 in endothelial cells. Am. J. Physiol., 1995, 269(pt. 1), 829-836.
69. Janssen-Heininger, Y.M.; Poynter, M.E.; Baeuerle, P.A. Recentadvances towards understainding redox mechanims in the activation of nuclear factor kappa B. Free Radic. Biol. Med., 2000, 28(9), 1317-1327.
70. Nishikawa, T.; Eldestein, D.; Dux, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Brownlee, M. Normalizing mitochondrialsuperoxide production blocks three pathways of hyperglycaemicdamage. Nature, 2000, 404, 787-790.
71. Martin-Gallan, P.; Carrascosa, A.; Gussinye, M.; Dominguez, C. Biomarkers of diabetes-associated oxidative stress and antioxidantstatus in young diabetic patients with or without subclinical complications. Free Radic. Biol. Med., 2003, 34(12), 1563-1574.
72. Dandona, P.; Thusu, K.; Cook, S.; Snyder, B.; Makowski, J.; Armstrong, D.; Nicotera, T. Oxidative damage to DNA in diabetes mellitus. Lancet, 1996, 347(8999), 444-445.
73. Gerrity, R.G. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol., 1981, 103, 191-200.
74. Kado, S.; Wakatsuki, T.; Yamamoto, M.; Nagata, N. Expression ofintercellular adhesion molecule-1 induced by high glucoseconcentrations in human aortic endothelial cells. Life. Sci., 2001, 68, 727-737.
75. Kim, J.A.; Berliner, J.A.; Natarajan, R.D.; Nadler, J.L. Evidencethat glucose increases monocyte binding to human aorticendothelial cells. Diabetes, 1994, 43, 1103-1107.
76. Morigi, M.; Angioletti, S.; Imberti, B.; Donadelli, R.; Micheletti, G.; Figliuzzi, M.; Remuzzi, A.; Zoja, C.; Remuzzi, G. Leukocyteendothelialinteraction is augmented by high glucoseconcentrations and hyperglycemia in a NF-kB-dependent fashion.J. Clin. Invest., 1998, 101, 1905-1915.
77. Haubner, F.; Lehle, K.; Munzel, D.; Schmid, C.; Birnbaum, D.E.; Preuner, J.G. Hyperglycemia increases the levels of vascularcellular adhesion molecule-1 and monocyte-chemoattractantprotein-1 in the diabetic endothelial cell. Biochem. Biophys. Res. Commun., 2007, 360, 560-565.
78. Scalia, R.; Coyle, K.M.; Levine, B.J.; Booth, G.; Lefer, A.M. Cpeptideinhibits leukocyte-endothelium interaction in themicrocirculation during acute endothelial dysfunction. FASEB. J., 2000, 14, 2357-2364.
79. Young, L.H.; Ikeda, Y.; Scalia, R.; Lefer, A.M. C-peptide exertscardioprotective effects in myocardial ischemia-reperfusion. Am. J. Physiol. Heart. Circ. Physiol., 2000, 279, H1453-459.
80. Nah, D.Y.; Rhee, M.Y. The inflammatory response and cardiacrepair after myocardial infarction. Korean Circ. J., 2009, 39(10), 393-398.
81. Luppi, P.; Cifarelli, V.; Tse, H.; Piganelli, J.; Trucco, M. Human Cpeptideantagonises high glucose-induced endothelial dysfunctionthrough the nuclear factor-kappaB pathway. Diabetologia, 2008, 51, 1534-1543.
82. Angus, D.C.; Linde-Zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky, M.R. Epidemiology of severe sepsis in theUnited States: analysis of incidence, outcome, and associated costsof care. Crit. Care. Med., 2001, 29(7), 1303-1310.
83. Bone, R.C. Toward an epidemiology and natural history of SIRS(systemic inflammatory response syndrome). JAMA, 1992, 268(24), 3452-3455.
84. Cai, B.; Deitch, E.A.; Ulloa, L. Novel insights for systemic inflammationin sepsis and hemorrhage. Mediat. Inflamm., 2010, 642462.
85. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L.; Vincent, J.L. Surviving Sepsis Campaign: international guidelines for managementof severe sepsis and septic shock: 2008. Intensive CareMed., 2008, 34(1), 17-60.
86. Sima, A.A.; Zhang, W.; Kreipke, C.W.; Rafols, J.A.; Hoffman, W.H. Inflammation in diabetic encephalopathy is prevented by Cpeptide. Rev. Diabet. Stud., 2009, 6(1), 37-42.
87. Li, Z.G.; Zhang, W.; Grunberger, G.; Sima, A. Hippocampal neuronalapoptosis in type 1 diabetes. Brain Res., 2002, 946(2), 221-231.
88. Sima, A.A.; Li, Z.G. The effect of C-peptide on cognitive dysfunctionand hippocampal apoptosis in type 1 diabetic rats. Diabetes, 2005, 54(5), 1497-1505.
89. Sima, A.A.; Zhang, W.; Muzik, O.; Kreipke, C.W.; Rafols, J.A.; Hoffman, W.H. Sequential abnormalities in type 1 diabetic encephalopathyand the effects of C-Peptide. Rev. Diabet. Stud., 2009, 6(3), 211-222.
90. Tak, P.P.; Firestein, G.S. NF-kappaB: a key role in inflammatorydiseases. J. Clin. Invest., 2001, 107, 7-11.
91. Baeuerle, P.A. I kappa B: a specific inhibitor of the NF-kappa Btranscription factor. Science, 1988, 242, 540-546.
92. Soares, M.P.; Muniappan, A.; Kaczmarek, E.; Koziak, K.; Wrighton, C.J.; Steinhauslin, F.; Ferran, C.; Winkler, H.; Bach, F.H.; Anrather, J. Adenovirus-mediated expression of a dominantnegative mutant of p65/RelA inhibits proinflammatory geneexpression in endothelial cells without sensitizing to apoptosis. J. Immunol., 1998, 161, 4572-14582.
93. Cifarelli. V.; Luppi, P.; Tse, H.M.; He, J.; Piganelli, J.; Trucco, M. Human proinsulin C-peptide reduces high glucose-inducedproliferation and NF-kappaB activation in vascular smooth musclecells. Atherosclerosis, 2008, 201, 248-257.
94. Kobayashi, Y.; Naruse, K.; Hamada, Y.; Nakashima, E.; Kato, K.; Akiyama, N.; Kamiya, H.; Watarai, A.; Nakae, M.; Oiso, Y.; Nakamura, J. Human proinsulin C-peptide prevents proliferation of rataortic smooth muscle cells cultured in high-glucose conditions. Diabetologia, 2005, 48(11), 2396-2401.
95. Al-Rasheed, N.M.; Chana, R.S.; Baines, R.J.; Willars, G.B.; Brunskill, N.J. Ligand-independent activation of peroxisomeproliferator-activated receptor-gamma by insulin and C-peptide inkidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J. Biol. Chem., 2004, 279, 49747-49754.
96. Pasceri, V.; Wu, H.D.; Willerson, J.T.; Yeh, E.T. Modulation ofvascular inflammation in vitro and in vivo by peroxisomeproliferator-activated receptor-gamma activators. Circulation, 2000, 101, 235-238.
97. Berger, J.P.; Akiyama, T.E.; Meinke, P.T. PPARs: therapeutictargets for metabolic disease. Trends. Pharmacol. Sci., 2005, 26, 244-251.
98. Lee, C.H.; Olson, P.; Evans, R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activatedreceptors. Endocrinology, 2003, 144, 2201-2207.
99. Rosen, E.D.; Spiegelman, B.M. PPARgamma: a nuclear regulatorof metabolism, differentiation, and cell growth. J. Biol. Chem., 2001, 276, 37731-37734.
100. Lehrke, M.; Lazar, M.A. The many faces of PPARgamma. Cell, 2005, 123, 993-999.
101. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. Cross-talkbetween nuclear receptors and nuclear factor kappaB. Oncogene, 2006, 25, 6868-6886.
102. Sasaki, M.; Jordan, P.; Welbourne, T.; Minagar, A.; Joh, T.; Itoh, M.;, Elrod, J.W.; Alexander, J.S. Troglitazone, a PPAR-gammaactivator prevents endothelial cell adhesion molecule expressionand lymphocyte adhesion mediated by TNF-alpha. BioMed. Central Physiol., 2005, 5(1), 3.
103. De Martin, R.; Hoeth, M.; Hofer-Warbinek, R.; Schmid, J.A. Thetranscription factor NF-kappa B and the regulation of vascular cellfunction. Arterioscler. Thromb. Vasc. Biol., 2000, 20(11), E83-88.
104. Duan, S.Z.; Usher, M.G.; Mortensen, R.M. Peroxisomeproliferator-activated receptor-gamma-mediated effects in thevasculature. Circ. Res., 2008, 102, 283-294.
105. Ido, Y.; Vindigni, A.; Chang, K.; Stramm, L.; Chance, R.; Heath, W.F.; DiMarchi, R.D.; Di Cera, E.; Williamson, J.R. Prevention ofvascular and neural dysfunction in diabetic rats by C-peptide. Science, 1997, 277, 563-566.
106. Flatt, P.R.; Swanston-Flatt, S.K.; Hampton, S.M.; Bailey, C.J.; Marks, V. Specific binding of the C-peptide of proinsulin tocultured B-cells from a transplantable rat islet cell tumor. Biosci. Rep., 1986, 6, 193-199.
107. Pramanik, A.; Ekberg, K.; Zhong, Z.; Shafqat, J.; Henriksson, M.; Jansson, O.; Tibell, A.; Tally, M.; Wahren, J.; Jornvall, H.; Rigler, R.; Johansson, J. C-peptide binding to human cell membranes:importance of Glu27. Biochem. Biophys. Res. Commun., 2001, 284, 94-98.
108. Rigler, R.; Pramanik, A.; Jonasson, P.; Kratz, G.; Jansson, O.T.; Nygren, P.; Stahl, S.; Ekberg, K.; Johansson, B.; Uhlen, S.; Jornvall, H.; Wahren, J. Specific binding of proinsulin C-peptide tohuman cell membranes. Proc. Natl. Acad. Sci. USA., 1999, 96, 13318-13323.
109. Lindahl, E.; Nyman, U.; Melles, E.; Sigmundsson, K.; Stahlberg, M.; Wahren, J.; Obrink, B.; Shafqat, J.; Joseph, B.; Jornvall, H. Cellular internalization of proinsulin C-peptide. Cell. Mol. Life. Sci., 2007, 64, 479-486.
110. Lindahl, E.; Nyman, U.; Zaman, F.; Palmberg, C.; Cascante, A.; Shafqat, J.; Takigawa, M.; Savendahl, L.; Jornvall, H.; Joseph, B. Proinsulin C-peptide regulates ribosomal RNA expression. J. Biol. Chem., 2010, 285, 3462-3469.
111. Luppi, P.; Geng, X.; Cifarelli, V.; Drain, P.; Trucco, M. C-peptideis internalised in human endothelial and vascular smooth musclecells via early endosomes. Diabetologia, 2009, 52, 2218-2228.
112. Gruenberg, J. The endocytic pathway: a mosaic of domains. Nat. Rev. Mol. Cell. Biol., 2001, 2, 721-730.
113. Miaczynska, M.; Pelkmans, L.; Zerial, M. Not just a sink: endosomesin control of signal transduction. Curr. Opin. Cell. Biol., 2004, 16, 400-406.
114. Di Guglielmo, G.M.; Baass, P.C.; Ou, W.J.; Posner, B.L.; Bergeron, J.J. Compartimentalization of SHC, GRB2 and mSOS, and hyperphosphosylation of Raf-1 by EGF but not insulin in liverparenchyma. EMBO. J., 1994, 13, 4269-4277.
115. Baass, P.C.; Di Guglielmo, G.M.; Authier, F.; Posner, B.L.; Bergeron, J.J. Compartmentalized signal transduction by receptortyrosine kinases. Trends Cell. Biol., 1995, 5, 465-470.
116. Grimes, M.L.; Zhou, J.; Beattie, E.C.; Yuen, E.C.; Hall, D.E.; Valletta, J.S.; Topp, K.S.; LaVail, J.H.; Bunnett, N.W.; Mobley, W.C. Endocytosis of activated trkA: evidence that nerve growth factorinduces formation of signaling endosomes. J. Neurosci., 1996, 16, 7950-7964.
117. Husebye, H.; Halaas, O.; Stenmark, H.; Tunheim, G.; Sandanger, O.; Bogen, B.; Brech, A.; Latz, E.; Espevik, T. Endocytic pathwaysregulate Toll-like receptor 4 signaling and link innate and adaptiveimmunity. EMBO. J., 2006, 25, 683-692.
118. Dodeller, F.; Gotar, M.; Huesken, D.; Iourhenko, V.; Cenni, B. Thelysosomal transmembrane protein 9B regulates the activity of inflammatorysignaling pathways. J. Biol. Chem., 2008, 283, 21487-21494.